Limited Value of Cystatin-C over Estimated Glomerular Filtration Rate for Heart Failure Risk Stratification

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Zamora, Elisabet ^a,b   Lupón, Josep ^a,b   de Antonio, Marta ^a,b   Vila, Joan ^c,d   Galán, Amparo ^a   Gastelurrutia, Paloma ^a   Urrutia, Agustín ^a,b   Bayes Genis, Antoni ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYSTATIN C;

AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT;

ADULT; AGED; BIOLOGICAL MARKERS; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT;

EID: 84871143622     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051234     Document Type: Article

References (32)

1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, et al. (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Eur Heart J 29: 2388-442.
2. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, et al. (2006) Renal impairment and outcomes in heart failure. Systematic review and meta-analysis. J Am Coll Cardiol 47: 1987-96.
3. De Santo NG, Cirillo M, Perna A, Pollastro RM, Frangiosa A, et al. (2005) The kidney in heart failure. Semin Nephrol 25: 404-7.
4. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R, (2002) Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a populationbased study. J Am Soc Nephrol 13: 1928-36.
5. de Silva R, Nikitin NP, Witte KK, Rigby AS, Goode K, et al. (2006) Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J 27: 569-81.
6. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW, (2004) Renal insufficiency and heart failure. Prognostic and therapeutic implications from a prospective cohort study. Circulation 109: 1004-9.
7. National Kidney Foundation (2002) K/DOQI clinical practice guidelines to define chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 39: S1-S266.
8. Cockroft DW, Gault MH, (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41.
9. Levey AS, Greene T, Kusek JW, Beck GJ, (2000) A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11 (suppl): 155A.
10. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, et al. (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-12.
11. Zamora E, Lupón J, Vila J, Urrutia A, de Antonio M, et al. (2012) Estimated glomerular filtration rate and prognosis in heart failure: Value of the Modification of Diet in Renal Disease study-4, Chronic Kidney Disease Epidemiology Collaboration, and Cockroft-Gault formulas. J Am Coll Cardiol 59: 1709-15.
12. Lassus J, Harjola V, Sund R, Siirilä-Waris K, Melin J, et al. (2007) Prognostic value of Cystatin-C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 28: 1841-47.
13. Shlipack MG, Katz R, Fried LF, Jenny NS, Stehman-Breen CO, et al. (2005) Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol 45: 268-71.
14. Bayes-Genis A, de Antonio M, Galan A, Sanz H, Urrutia A, et al. (2012) Combined Use of High Sensitivity ST2 and NTproBNP to Improve the Prediction of Death in Heart Failure. Eur J Heart Fail 14: 32-8.
15. Pencina MJ, D'Agostina RB, Steyerberg EW, (2011) Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Statist Med 30: 11-21.
16. Turk V, Bode W, (1991) The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett 285: 213-9.
17. Coll E, Botey A, Álvarez L, Poch E, Quintó L, et al. (2000) Serum Cystatin-C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 36: 29-34.
18. O'Riordan SE, Welb MC, Stowe HJ, Simpson DE, Kondarpa M, et al. (2003) Cystatin-C improves the detection of mild renal dysfunction in older patients. Ann Clin Biochem 40: 648-55.
19. Hoek FJ, Kemperman FA, Krediet RT, (2003) A comparison between Cystatin-C, plasma creatinine and the Cockroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 18: 2024-31.
20. Odden MC, Tager IB, Gansevoort RT, Bakker SJ, Katz R, et al. (2010) Age and Cystatin-C in healthy adults: A collaborative study. Nephrol Dial Transplant 25: 463-9.
21. Knight EL, Verhave JC, Spiegelman D, Hillege HL, De Zeeuw DD, et al. (2004) Factors influencing serum Cystatin-C levels other than renal function and the impact on renal function measurement. Kidney Int 65: 1416.
22. Mc Murray MD, Trivax JE, McCullough PA, (2009) Serum Cystatin-C, renal filtration function, and left ventricular remodeling. Circ Heart Fail 2: 86-9.
23. Ix JH, Shlipack MG, Chertow GM, Whooley MA, (2007) Association of Cystatin-C with mortality, cardiovascular events, and incidente heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 115: 173-79.
24. Waheed S, Matsushita K, Sang Y, Hoogeveen R, Ballantyne C, et al. (2012) Combined association of albuminuria and Cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 24[Epub ahead of print].
25. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, et al. (2005) Cystatin-C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352: 2049-60.
26. Cheng XW, Obata K, Kuzuya M, (2006) Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension 48: 979-87.
27. Ix JH, Shlipack MG, Chertow GM, Ali S, Schiller NB, et al. (2006) Cystatin-C, left ventricular hypertrophy, and diastolic dysfunction: Data from the Heart and Soul Study. J Card Fail 12: 601-07.
28. Naruse H, Ishii J, Kawai T, Hattori K, Ishikawa M, et al. (2009) Cystatin-C in acute heart failure without advanced renal impairment. Am J Med 122: 566-73.29.
29. Gao C, Zhong L, Gao Y, Li X, Zhang M, et al. (2011) Cystatin C levels are associated with the prognosis of systolic heart failure patients. Arch Cardiovasc Dis 104: 565-71.
30. Arimoto T, Takeishi Y, Niizeki T, Takabatake N, Okuyama H, et al. (2005) Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure. J Card Fail 11: 595-601.
31. Damman K, van der Harst P, Smilde TDJ, Voors AA, Navis G, et al. (2012) Use of Cystatin-C levels in estimating renal function and prognosis in patients with chronic systolic heart failure. Heart 98: 319-24.
32. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, et al. (2009) Criteria for Evaluation of Novel Markers of Cardiovascular Risk. A Scientific Statement From the American Heart Association. Circulation 119: 2408-16.